Verisk Analytics, Inc. Free cash flow increased by 18.2% to $326.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 16.5%, from $391.00M to $326.40M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 7.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $170.70M | $223.80M | $103.30M | $339.60M | $61.00M | $214.40M | $169.30M | $304.10M | $134.70M | $195.80M | $196.10M | $317.00M | $153.90M | $240.70M | $200.00M | $391.00M | $188.70M | $336.10M | $276.10M | $326.40M |
| QoQ Change | — | +31.1% | -53.8% | +228.8% | -82.0% | +251.5% | -21.0% | +79.6% | -55.7% | +45.4% | +0.2% | +61.7% | -51.5% | +56.4% | -16.9% | +95.5% | -51.7% | +78.1% | -17.9% | +18.2% |
| YoY Change | — | — | — | — | -64.3% | -4.2% | +63.9% | -10.5% | +120.8% | -8.7% | +15.8% | +4.2% | +14.3% | +22.9% | +2.0% | +23.3% | +22.6% | +39.6% | +38.0% | -16.5% |